Identify Cell Surface Receptors With the LRC-TriCEPS Technology

Physiological reactions to peptides, proteins or drugs are generally mediated through interactions with cell surface receptors. To identify these receptors_several technologies _can be applied. LRC-TriCEPS is one of them. It allows the identification of cell surface receptors and off-targets on living cells.

The company Dualsystems applies this technology to their customers’ projects. Scientist asked Paul Helbling, CEO at Dualsystems, a few questions about this its activities.

Dr. Helbling, tell us more about you.

I did my Ph.D. in developmental biology. I was elucidating the function of EPH receptor tyrosine kinases in the embryonic development. I have 15 years experience in several service provider companies working according to the different quality standards (GLP, GMP, GCP). Now at Dualsystems Biotech AG, I am happy to investigate again the interaction of living cells with the extracellular environment.

About your company, what is its history, its mission?

Dualsystems was founded in 2000. It originally worked on protein-protein interaction using a yeast-based technology. In 2013 we sold the yeast part to another service provider to focus on the LRC-TriCEPS technology. This technology identifies targets of different types of ligands on living mammalian cells: peptides, proteins, antibodies, ADC, viruses and now also small molecules.

### What services do Dualsystems offer?

1) LRC-TriCEPS (LC-MS/MS-based) to identify the targets of biologics (peptides, proteins, antibodies, ADC’s, viruses) on living cells.
2) Flow-TriCEPS (Flow cytometry-based) to identify the best binding conditions of your ligand before the main identification study and to confirm identified target candidates using siRNA.
3) LRC-HATRIC (LC-MS/MS-based) to identify the targets of small molecules on living cells.

What sets your expertise apart from others?

Dualsystems Biotech has the worldwide exclusive license to use the LRC-TriCEPS and the LRC-HATRIC technologies to identify targets on the living cells and study the mode of action of a drug.

What challenges are you currently addressing?

We develop the technology to visualize the binding of ligands on the living cells using fluorescence microscopy. Also, we develop means to have a fast and easy way to validate identified targets using Flow-TriCEPS combined with siRNA knockdown.

Dualsystems has Scientist. What do you expect from it?

We expect to get in contact with innovative companies that want to:
- elucidate the mode of action of their drugs,
- identify off-targets, identify proteins important for cell-cell interaction.
Dualsystems aims to support them with our innovative technologies.

If you are interested in knowing more about Dualsystems’ offer, visit its profile.